UAE Blood Plasma Market Analysis

UAE Blood Plasma Market Analysis


$ 3999

UAE Blood Plasma Market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 - 2030. Rising demand for plasma-derived therapies, advancements in plasma fractionation technologies, rising awareness and adoption of plasma-derived therapies, a favourable regulatory environment, increased investment in plasma collection centres, and a growing need for blood plasma in research and development are key drivers in the blood plasma market. CSL Behring, Grifols, Octapharma, Biotest AG, and Kedrion are some of the major global competitors in the blood plasma industry.

ID: IN10AEPH248 CATEGORY: Pharmaceuticals GEOGRAPHY: UAE AUTHOR: Aneri Parekh

Buy Now

UAE Blood Plasma Market Analysis Summary

UAE Blood Plasma Market is valued at around $169.4 Mn in 2022 and is projected to reach $343 Mn by 2030, exhibiting a CAGR of 9.22% during the forecast period 2023-2030.

The global market for blood plasma and plasma-derived products is referred to as the blood plasma market. The liquid component of blood that remains after the removal of red and white blood cells, platelets, and other biological components is known as blood plasma. Plasma has a high concentration of proteins, including antibodies, clotting factors, and albumin, which are used in a variety of therapeutic applications. Blood plasma collection centers, plasma fractionation, and the manufacturing of plasma-derived products such as immunoglobulins, albumin, clotting factors, and alpha-1 antitrypsin are all part of the blood plasma industry. The blood plasma market seeks to collect, process, and use blood plasma and its derivatives to suit patients' medicinal needs. Rising demand for plasma-derived therapies, advancements in plasma fractionation technologies, rising awareness and adoption of plasma-derived therapies, a favorable regulatory environment, increased investment in plasma collection centers, and a growing need for blood plasma in research and development are key drivers in the blood plasma market. CSL Behring, Grifols, Octapharma, Biotest AG, and Kedrion are some of the major global competitors in the blood plasma industry.

Market Dynamics

Market Growth Drivers

  1. Increasing Interest in Plasma-Derived Therapies: Plasma-derived therapies are used to treat a variety of ailments, including immunological deficiencies, bleeding problems, neurological issues, and autoimmune diseases. The increasing frequency of these disorders fuels the demand for plasma and plasma-derived products
  2. Rising Adoption and Awareness of Plasma-Derived Therapies: Increased knowledge of the benefits of plasma-derived medicines among healthcare professionals and patients has resulted in wider acceptance. Plasma treatments provide effective treatment choices for a wide range of disorders, fueling market growth
  3. Technological Advances in Plasma Fractionation and Collection: Advances in plasma fractionation and collection procedures have increased the efficiency and safety of plasma-derived products. As a result, production capabilities have risen and the availability of plasma-derived medicines has expanded, promoting market expansion
  4. Increasing Investment in Plasma Collection Facilities: The creation of plasma donation centers, where people can donate plasma, has improved the availability of plasma for the production of plasma-derived goods. Growing investment in these centers helps address rising plasma demand and drives market expansion

Market Restraints

  1. The blood plasma market faces challenges such as the risk of infectious diseases associated with plasma collection, stringent regulatory requirements, and ethical considerations related to compensation for plasma donations

Competitive Landscape

Key Players

  • CSL Behring
  • Grifols
  • Octapharma
  • Biotest AG
  • Kedrion

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

UAE Blood Plasma Market Segmentation

By Product Type

  • Albumin
  • Anti-inhibitor Coagulation Factor
  • Factor VIII
  • Factor IX Concentrate
  • Immunoglobulins
  • Rh Immunoglobulin
  • Alpha 1-Protease Inhibitor
  • Anti-Thrombin

By Application

  • HIV
  • Hemophilia A
  • Hemophilia B
  • Hepatitis C
  • Bleeding Disorders
  • Genetic Lung Disorders
  • Immune Deficiency System
  • Liver Conditions
  • Viral Disease

By End User

  • Hospital
  • Clinic
  • Transfusion Center
  • Others

By Distribution Channel

  • Hospitals
  • Clinic
  • Emergency Service Centers
  • Ambulatory Surgical Centers
  • Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.​

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

  • Analyzing historical proprietary data collected from multiple projects.
  • Regularly updating our existing data sets with new findings and trends.
  • Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

  • Searching through academic conferences, published research, citations, and social media platforms
  • Collecting and compiling diverse data to build a comprehensive and detailed database
  • Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

  • Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
  • Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
  • Continuously refreshing our database to ensure that the information remains current and reliable.
  • Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

  • Merging historical data from secondary research with real-time data from primary research.
  • Conducting thorough data validation and cleansing to remove inconsistencies and errors.
  • Organizing data into a structured format that is easily accessible and usable for various applications.
  • Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.

To request a free sample copy of this report, please complete the form below.


We value your inquiry and offer free customization with every report to fulfil your exact research needs.


Last updated on: 27 February 2024
Updated by: Bhanu Pratap Singh

Related reports (by category)


Related reports (by geography)


subscribe to our newsletter
up